This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Porphyria

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The porphyrias are a group of disorders caused by defects in the synthesis of haem.

Hepatic porphyrias:

  • acute intermittent porphyria (AIP)
  • variegate porphyria (VP)
  • hereditary coproporphyria (HCP)
  • aminolevulinic acid dehydratase porphyria (ADP), of which only six definite cases have been reported (1)
  • porphyria cutanea tarda (PCT)

Erythropoietic porphyrias:

  • erythropoietic porphyria (EP)
  • erythropoietic protoporphyria (EPP)
  • erythropoietic coproporphyria (ECP)

Hepatic / erythropoietic:

  • hepatoerythropoietic porphyria (HEP)

In hepatic porphyrias there is excess hepatic production of porphobilinogen. In erythropoietic porphyrias there is increased production of porphyrins in red blood cells due to enzyme deficiency.

A useful classification divides porphyrias into acute and non-acute:

  • porphyrias have been subdivided into hepatic and erythropoietic forms, according to the site of expression of the dysfunctional enzyme
    • although may be classified according to their clinical manifestations- as acute (neurovisceral) versus non-acute (cutaneous) porphyrias
    • acute neurovisceral forms are characterized by overproduction of delta-aminolevulinic acid (ALA) and porphobilinogen (PBG), which are porphyrin precursors, at the initial steps of heme synthesis
    • cutaneous porphyrias are characterized by accumulation of porphyrins, which are the precursors at the final steps of the synthesis
  • in some of the acute porphyria types both neurovisceral and cutaneous symptoms may be present (2)

Notes:

  • accumulated precursors are excreted in the urine, in the feces, or in both - according to their solubility -and measuring their level is the basis of porphyria biochemical diagnosis and typing
  • heme
    • is the final product of the pathway
    • is essential for the synthesis of hematoproteins such as hemoglobin, myoglobin, microsomal cytochromes, catalase and others
      • all of which play an important role in oxygen transport and/or oxidation–reduction reactions
      • most of heme synthesis in human beings (80%) takes place in erythropoietic cells, while about 15% is produced in the liver parenchymal cells
    • the most important site of control is the first step in the synthesis, ALA formation
      • catalyzed by the enzyme ALA synthase (ALAS), which has two subtypes
        • ALAS1, the ubiquitous one, encoded on chromosome 3,
        • ALAS2, erythroid-specific, encoded on chromosome X
        • in the erythropoietic tissue, regulation of heme synthesis is influenced by erythroid differentiation and erythropoietin and iron availability
        • in the liver, ALAS1 is under negative feedback regulation by the intracellular heme pool
      • the levels of delta-aminolevulinate are elevated in all patients with porphyria because of the loss of feedback inhibition of d-ALA synthase by haem
      • haem usually prevents the translation of d-ALA synthase by activating a protein which binds to the 5'-untranslated region of the mRNA
      • in acute porphyrias the activity of porphobilinogen deaminase is either normal or low resulting in the accumulation of porphobilinogen (PBG). The combination of high d-ALA and PBG results in the abdominal pain and neuropsychiatric features
      • in non-acute porphyrias the acitivity of PBG deaminase is elevated and so PBG does no accumulate. There are specific defects in the the subsequent metabolism of proto-porphyrins. Accumulation of protoporphyris causes the photosensitivity

Reference:

  • Edel Y, Mamet R. Porphyria: What Is It and Who Should Be Evaluated?. Rambam Maimonides Med J. 2018;9(2):e0013. Published 2018 Apr 19. doi:10.5041/RMMJ.10333
  • Karim Z, Lyoumi S, Nicolas G, Deybach JC, Gouya L, Puy H. Porphyrias: a 2015 update. Clin Res Hepatol Gastroenterol. 2015;39:412–25

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.